10-K: OSR Holdings Completes Business Combination with Bellevue Life Sciences Acquisition Corp., Faces Financial Hurdles

OSR Holdings, a global healthcare company, finalized its merger with Bellevue Life Sciences Acquisition Corp., but faces immediate financial challenges due to a canceled PIPE investment and existing debt.

Summary

• OSR Holdings, Inc. completed a business combination with Bellevue Life Sciences Acquisition Corp. on February 14, 2025.
• The company's vision is to acquire and operate a portfolio of innovative health-care related companies globally.
• OSR Holdings operates through three wholly-owned subsidiaries, focusing on oral immunotherapies for cancer, design-augmented biologics for degenerative diseases, and neurovascular intervention medical device distribution in Korea.
• The company's strategy involves acquiring or licensing assets, attracting industry partners, and potentially raising capital from private, strategic, or public investors.
• A previously agreed $20 million PIPE transaction was canceled, leaving the company insolvent at the closing of the Business Combination.
• The company is seeking alternative financing arrangements to fund operations and pay outstanding debts.
• There is substantial doubt about the Companys ability to continue as a going concern.
• The company is an emerging growth company and a smaller reporting company, which allows for certain exemptions from reporting requirements.
• The company's executive offices are located in Bellevue, WA and Paju, Gyeonggi-do, Korea.
• The company has five officers who intend to devote as much time as necessary to the company's affairs.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the business combination is complete, the financial instability due to the canceled PIPE investment and the need for additional capital raise significant concerns. The presence of material weaknesses in internal controls further dampens the sentiment.

Positives

• The company has a diverse portfolio of scientific and technological developments through its subsidiaries.
• The company owns or licenses numerous patents and intellectual property.
• The company has a hub-and-spoke business model with a centralized executive team partnering with subsidiary management teams.
• The company has established close relationships with leading university hospitals and general hospitals in Korea to supply cerebrovascular surgery equipment.

Negatives

• A previously agreed $20 million PIPE transaction was canceled, leaving the company insolvent at the closing of the Business Combination.
• The company was insolvent at the closing of the Business Combination and will not have enough cash to fund its operations or pay its outstanding expenses and debts.
• The company has identified material weaknesses in its internal control over financial reporting.
• The Company management team has limited experience managing and operating a U.S. public company.
• The Companys limited operating history, the early stage of its development programs and the inherent uncertainties and risks involved in pharmaceutical product development may make it difficult for it to execute on its business model.
• The Company will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability.

Risks

• The company's Chief Executive Officer and one of its directors was previously the Chief Executive Officer and is currently the Chairman of the Board of OSR, creating potential conflicts of interest.
• The company may not be successful in securing alternative funding, potentially leading to bankruptcy proceedings.
• The company's only significant asset will be its ownership of OSR, which may not be sufficient to pay its expenses or satisfy other financial obligations.
• The price of the company's common stock and warrants may be volatile.
• An active, liquid trading market for the company's common stock and warrants may not develop or persist.
• The company's limited operating history and early-stage development programs may make it difficult to execute its business model.
• The company will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability.
• The company may not be successful in acquiring, in-licensing, or discovering and developing new product candidates.
• The company currently has no marketing and sales organization for pharmaceutical products and has no experience as a company in commercializing products.
• The company will require substantial additional capital to finance its operations.
• The company will incur increased costs as a result of operating as a public company.
• If economic conditions in South Korea deteriorate, the company's current business and future growth could be materially and adversely affected.
• The company currently outsources much of its discovery, clinical development, and manufacturing functions to third-party providers or consultants.
• If the company is unable to obtain and maintain patent and other intellectual property protection for its technology and product candidates, it may not be able to compete effectively in its markets.

Future Outlook

The company anticipates optimizing commercial value through various options, including internal advancement, strategic partnerships, and spin-outs or public offerings. The company expects to continue to incur operating losses and negative cash flows in the future.

Industry Context

The announcement reflects a trend of SPAC mergers in the healthcare sector, where companies seek to go public through alternative routes. The company operates in a competitive landscape with established pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• Vaximm's competitors include AbbVie, AstraZeneca, Bayer, DNAtrix, VBL Therapeutics, Aivita Biomedical, and Kintara Therapeutics, all developing therapies for glioblastoma.
• Darnatein's competitors in osteoarthritis treatment include Kolon TissueGene, Biosplice Therapeutics, and Merck KGaA/EMD serono.
• Darnatein's competitors in orthopedic solutions include Medtronic, NuVasive, Stryker, Cerapedics, and Novabone.
• RMC's competitors in neurovascular intervention include Medtronic, Stryker Neurovascular, Microvention, Cerenovous, and Boston Scientific.

Legal Proceedings

• In March of 2025 Company Management became aware of a civil action filed against the Company by Benjamin Securities, Inc. in Supreme Court, New York County, seeking $500,000.00 in brokerage fees and costs the plaintiff alleges are due and owing.

Related Party Transactions

• The company has entered into various transactions with its Sponsor and affiliates, including loans, administrative support agreements, and transfers of founder shares.
• The company has issued promissory notes to related parties, including Jun Chul Whang and Bellevue Global Life Sciences Investors, LLC.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial instability and potential need for cost reductions.
• Customers may be affected by potential disruptions in the supply chain or changes in product offerings.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company will seek alternative financing arrangements to fund operations and pay outstanding debts.
• The company will focus on advancing its preclinical and clinical development programs.
• The company will work to improve its internal control over financial reporting.
• The company will seek to replace sales of Penumbra products by becoming the sales representative of other neuro-intervention medical device equipment manufacturers, as well as expanding sales of products offered by companies it currently represents.

Key Dates

Keywords

Business Combination, OSR Holdings, Bellevue Life Sciences, PIPE Investment, Financial Insolvency, Drug Development, Healthcare, Merger, Acquisition, Biologics, Immunotherapy, Medical Devices